Last updated: February 16, 2026
Overview of the Drug
NDC 69452-0126 corresponds to Sogroya (somapacitan-beco), a once-weekly human growth hormone analog approved by the FDA in August 2020 for treating growth hormone deficiency (GHD) in adults. It is marketed by Novo Nordisk.
Market Size and Demand Drivers
- The adult GHD market is estimated to be worth approximately $400 million globally in 2022.
- U.S. prevalence of adult GHD is approximately 70,000 cases, with underdiagnosis estimated at 30-50%.
- Growth is driven by increased awareness, improved diagnostics, and expanding insurance coverage.
Competitive Landscape
- Main competitors include Norditropin (Novo Nordisk), Genotropin (Pfizer), and Saizen (Eli Lilly).
- Sogroya's once-weekly formulation offers convenience over daily injections, aligning with patient preferences.
- Market penetration remains modest; estimates suggest a 10-15% share among growth hormone therapies as of 2022.
Regulatory and Reimbursement Environment
- U.S. Medicare Part D and private insurers cover Sogroya but with prior authorization requirements.
- Off-label use is minimal; most prescriptions target approved GHD indications.
- Price negotiations and PBM contracts influence access and utilization rates.
Pricing Data and Trends
- Wholesale Acquisition Cost (WAC): approximately $4,150 per 4.5 mg dose (exact prices vary by pharmacy and location).
- Annual treatment costs for adults average $45,000–$50,000, aligning comparably with other long-acting growth hormone therapies.
- Price adjustments have been limited since launch; inflation-adjusted pricing stable over 2021-2022.
Price Projections
| Year |
Estimated WAC per Dose |
Approximate Annual Cost |
Assumptions |
| 2023 |
$4,150 |
$45,000–$50,000 |
Stable pricing, current market share |
| 2024 |
$4,150–$4,300 |
$45,000–$55,000 |
Slight increase for inflation, demand rise |
| 2025 |
$4,250–$4,300 |
$45,000–$60,000 |
Market expansion, potential price adjustments |
Projected pricing indicates minimal fluctuations barring changes in regulatory strategies or significant market entry of biosimilars.
Key Market Factors Influencing Price and Adoption
- Patent expiry for original formulations could catalyze biosimilar entry around 2025–2026.
- Cost-sharing dynamics in insurance plans could influence patient adoption.
- Increase in off-label uses or new indications (e.g., pediatric GHD) could expand market size and influence pricing strategies.
- Patient adherence benefits attributed to weekly dosing could support premium pricing models.
Conclusion
NDC 69452-0126's market is characterized by a stable pricing environment with gradual growth driven by market expansion and competitive positioning. Price projections remain stable with potential upward adjustments aligned with inflation and market penetration enhancements.
Key Takeaways
- The adult GHD market is valued at approximately $400 million, with Sogroya capturing a modest market share.
- Current WAC is around $4,150 per dose, translating to an annual cost of $45,000–$50,000.
- Price stability persists; biosimilar competition expected to emerge by 2025–2026.
- Market growth depends on increased diagnosis, insurance coverage, and new clinical indications.
- Expansion into pediatric markets could influence demand and pricing strategies.
FAQs
-
When are biosimilars for Sogroya expected?
Biosimilar pathways typically take 5–7 years from approval. Entry could occur around 2025–2026, assuming patent expirations and regulatory approvals align.
-
How does Sogroya compare cost-wise to daily growth hormone therapies?
Annual costs are comparable, with Sogroya’s weekly regimen potentially improving adherence and reducing administration-related costs.
-
What reimbursement challenges could impact pricing?
Insurance prior authorizations, formulary placements, and negotiations with PBMs influence accessible pricing and reimbursement rates.
-
Are there off-label uses affecting the market?
While primarily approved for adult GHD, exploratory off-label applications are rare, marginally impacting market size.
-
How might new indications influence future pricing?
Expansion into pediatric GHD or other hormonal deficiencies could increase demand, possibly leading to incremental price adjustments.
References
[1] IQVIA, "U.S. Growth Hormone Market Data," 2022.
[2] FDA, "Approval Letter for Sogroya," August 2020.
[3] Novo Nordisk, "Sogroya Product Information," 2022.
[4] MarketWatch, "Growth Hormone Market Analysis," 2022.
